Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Detalhes bibliográficos
Autor(a) principal: Rondy, Marc
Data de Publicação: 2018
Outros Autores: Kissling, Esther, Emborg, Hanne-Dorthe, Gherasim, Alin, Pebody, Richard, Trebbien, Ramona, Pozo, Francisco, Larrauri, Amparo, McMenamin, Jim, Valenciano, Marta, I-Move/I-Move Group
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Texto Completo: http://hdl.handle.net/10400.18/5719
Resumo: Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
id RCAP_df3bd3fb6aff4b8a89fca8c15ed60688
oai_identifier_str oai:repositorio.insa.pt:10400.18/5719
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studiesInfluenza VaccineVacina AntigripalDeterminantes da Saúde e da DoençaVaccine EffectivenessCuidados de SaúdeEuropeCase control studyInfluenzaInfluenza VaccinationInfluenza Vaccine EffectivenessMulticentre StudyBetween September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.European Centre for Disease Prevention and ControlRepositório Científico do Instituto Nacional de SaúdeRondy, MarcKissling, EstherEmborg, Hanne-DortheGherasim, AlinPebody, RichardTrebbien, RamonaPozo, FranciscoLarrauri, AmparoMcMenamin, JimValenciano, MartaI-Move/I-Move Group2019-02-06T17:46:21Z2018-032018-03-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/5719eng1025-496X10.2807/1560-7917.ES.2018.23.9.18-00086info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-02-26T14:25:22Zoai:repositorio.insa.pt:10400.18/5719Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T21:40:19.383619Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
title Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
spellingShingle Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
Rondy, Marc
Influenza Vaccine
Vacina Antigripal
Determinantes da Saúde e da Doença
Vaccine Effectiveness
Cuidados de Saúde
Europe
Case control study
Influenza
Influenza Vaccination
Influenza Vaccine Effectiveness
Multicentre Study
title_short Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
title_full Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
title_fullStr Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
title_full_unstemmed Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
title_sort Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
author Rondy, Marc
author_facet Rondy, Marc
Kissling, Esther
Emborg, Hanne-Dorthe
Gherasim, Alin
Pebody, Richard
Trebbien, Ramona
Pozo, Francisco
Larrauri, Amparo
McMenamin, Jim
Valenciano, Marta
I-Move/I-Move Group
author_role author
author2 Kissling, Esther
Emborg, Hanne-Dorthe
Gherasim, Alin
Pebody, Richard
Trebbien, Ramona
Pozo, Francisco
Larrauri, Amparo
McMenamin, Jim
Valenciano, Marta
I-Move/I-Move Group
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Nacional de Saúde
dc.contributor.author.fl_str_mv Rondy, Marc
Kissling, Esther
Emborg, Hanne-Dorthe
Gherasim, Alin
Pebody, Richard
Trebbien, Ramona
Pozo, Francisco
Larrauri, Amparo
McMenamin, Jim
Valenciano, Marta
I-Move/I-Move Group
dc.subject.por.fl_str_mv Influenza Vaccine
Vacina Antigripal
Determinantes da Saúde e da Doença
Vaccine Effectiveness
Cuidados de Saúde
Europe
Case control study
Influenza
Influenza Vaccination
Influenza Vaccine Effectiveness
Multicentre Study
topic Influenza Vaccine
Vacina Antigripal
Determinantes da Saúde e da Doença
Vaccine Effectiveness
Cuidados de Saúde
Europe
Case control study
Influenza
Influenza Vaccination
Influenza Vaccine Effectiveness
Multicentre Study
description Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
publishDate 2018
dc.date.none.fl_str_mv 2018-03
2018-03-01T00:00:00Z
2019-02-06T17:46:21Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.18/5719
url http://hdl.handle.net/10400.18/5719
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1025-496X
10.2807/1560-7917.ES.2018.23.9.18-00086
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv European Centre for Disease Prevention and Control
publisher.none.fl_str_mv European Centre for Disease Prevention and Control
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833599374581563392

Registros relacionados